 OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease status at study entry metastatic vs recurrent vs persistent, prior cisplatin as a radiosensitizer yes vs no, and extent of disease confined to pelvis vs extrapelvic disease. Patients are randomized to 1 of 2 treatment arms. 